Ranjana Advani, MD; Stanford University #BtC_ASCO21
Dr. Ranjana Advani shares strategies for Integrating Recently Approved Therapies for B-cell NHL Into Practice.
Maria-Victoria Mateos, MD, PhD; University of Salamanca #BtC_ASCO21
Dr. Maria-Victoria Mateos discusses Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory MM
Jennifer R. Brown, MD, PhD; Dana-Farber Cancer Institute #BtC_ASCO21
Dr. Jennifer Brown reviews Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory CLL.
Gail Roboz, MD; Weill Cornell Medicine #BtC_ASCO21
Dr. Gail Roboz presents on Personalizing Therapy for Adult Patients with ALL.
Selina Luger, MD, FRCPC; University of Pennsylvania #BtC_ASCO21
Dr. Selina Luger discusses Biomarkers and their Implications for Therapy in AML.
John P. Leonard, MD; Weill Cornell Medicine #BtC_ASCO21
Dr. John Leonard discusses Recently Presented Data of Clinical Trials in Patients with NHL.
Matthew Davids, MD, MMSc; Dana-Farber Cancer Inst. #BtC_ASCO21
Dr. Matthew Davids reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for CLL.
Alison J. Moskowitz, MD; Memorial Sloan Kettering Cancer Center #BtC_ASCO21
Dr. Alison Moskowitz presents on Treatments for Upfront and Relapsed Hodgkin’s Lymphoma.
Sagar Lonial, MD, FACP; Emory University #BtC_ASCO21
Dr. Sagar Lonial reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for MM
Nina Shah, MD; UCSF Health #BtC_ASCO21
Dr. Nina Shah reviews Considerations for the Community Provider in Using CAR T-Cell Therapies for MM
Nicole Lamanna, MD; Columbia University #BtC_ASCO21
Dr. Nicole Lamanna discusses Practical Issues in Treating CLL: Sequencing, Oral Adherence, Managing Adverse Events, and MRD Analysis.
- Next Page